Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Earnings per Share (Diluted) : $0.40 (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Earnings per Share (Diluted)?

Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.23. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.40.

Takeda Pharmaceutical Co's EPS (Basic) for the three months ended in Dec. 2023 was $0.24. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.41.

Takeda Pharmaceutical Co's EPS without NRI for the three months ended in Dec. 2023 was $0.23. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.40.

During the past 12 months, Takeda Pharmaceutical Co's average EPS without NRIGrowth Rate was -35.90% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 35.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 12.70% per year.

During the past 13 years, Takeda Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 35.60% per year. The lowest was -24.60% per year. And the median was 3.00% per year.

Takeda Pharmaceutical Co Earnings per Share (Diluted) Historical Data

The historical data trend for Takeda Pharmaceutical Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Earnings per Share (Diluted) Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

0.63

0.13

1.10

0.62

0.76

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															0.28	0.07	0.20	-0.10	0.23

Competitive Comparison of Takeda Pharmaceutical Co's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takeda Pharmaceutical Co's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's PE Ratio falls into.

Takeda Pharmaceutical Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Takeda Pharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (A: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(2371.74	-	0)	/	3139.744
	=	0.76

Takeda Pharmaceutical Co's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(734.261	-	0)	/	3178.764
	=	0.23

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.40

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Takeda Pharmaceutical Co (NYSE:TAK) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Takeda Pharmaceutical Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.